BioSpace
Episodes
The top life sciences startups to watch this year
03 Jan 2024
Contributed by Lukas
Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Clas...
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
21 Dec 2023
Contributed by Lukas
How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadick...
Every move you make: Biopharma industry under heavy scrutiny
20 Dec 2023
Contributed by Lukas
Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; mean...
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
14 Dec 2023
Contributed by Lukas
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding o...
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
13 Dec 2023
Contributed by Lukas
That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing the...
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
12 Dec 2023
Contributed by Lukas
This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and I...
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
07 Dec 2023
Contributed by Lukas
Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is h...
GLP-1 and ADC rollercoasters pick up speed
06 Dec 2023
Contributed by Lukas
The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medici...
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
05 Dec 2023
Contributed by Lukas
Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI mo...
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
30 Nov 2023
Contributed by Lukas
The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patien...
Deals, Dupixent and GLP-1 drug shortages
29 Nov 2023
Contributed by Lukas
This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ...
First ever CRISPR gene therapy approval: What happens next?
21 Nov 2023
Contributed by Lukas
Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autote...
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
16 Nov 2023
Contributed by Lukas
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bia...
Zepbound vs Wegovy: A two horse race
15 Nov 2023
Contributed by Lukas
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegov...
Q3 earnings recap: Winners, losers & surprises
08 Nov 2023
Contributed by Lukas
This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma'...